Objective: To explore the application value of montelukast sodium combined with carosulfone sodium on children with Henoch-Schöenlein purpura. Methods: Totally 128 children with Henoch-Schöenlein purpura admitted into our hospital from Jan. 2014 to Jan. 2017 were extracted to be divided into the control group and the study group via the random number table

with 64 cases in each group. The basic treatment and nursing of two groups were the same. The study group was treated with montelukast sodium combined with calosulfonate sodium

while the control group received montelukast sodium. The disappearance time of clinical symptoms

clinical efficacy

adverse drug reactions and levels of IL-6

TNF-α

recombinant suppressors of cytokine signaling 3 (SOCS3) and galactose-deficient IgA1 (Gd-IgA1) of two groups were observed. Results: The disappearance time of skin purpura

digestive tract disease

joint swelling and pain

kidney disease of the study group was shorter than that of the control group (P<0.01). The total effective rate of the study group was 93.75%

higher than 73.44% of the control group (P<0.01). The incidence of adverse drug reactions in the study group was 20.31%

compared with 18.75% in the control group

the difference was not statistically significant (P>0.05). After treatment

the levels of IL-6

TNF-α

SOCS3 mRNA and Gd-IgA1 in two groups decreased significantly

and the study group was lower than the control group (P<0.05). Conclusion: Montelukast sodium combined with carosulfone sodium in the treatment of children with Henoch-Schöenlein purpura is significant

which can reduce the inflammatory response and levels of serum SOCS3 and Gd-IgA1 and improve capillary permeability. It is worthy of clinical application.